Foundry Healthcare Book-to-Market Value Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1BMRN | BIOMARIN PHARMACEUTICAL INC | Healthcare | $11.52B | 15.83% |
2OSCR | OSCAR HEALTH INC | Healthcare | $8.77B | 12.06% |
3BIO | BIO-RAD LABORATORIES INC | Healthcare | $8.15B | 11.19% |
4BEAM | BEAM THERAPEUTICS INC | Healthcare | $2.83B | 3.89% |
5AGIO | AGIOS PHARMACEUTICALS INC | Healthcare | $2.36B | 3.24% |
6AGL | AGILON HEALTH INC | Healthcare | $2.17B | 2.98% |
7ABCL | ABCELLERA BIOLOGICS INC | Healthcare | $1.97B | 2.71% |
8HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.96B | 2.69% |
9SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.82B | 2.50% |
10MPLT | MAPLIGHT THERAPEUTICS INC | Healthcare | $1.72B | 2.36% |
11INVA | INNOVIVA INC | Healthcare | $1.60B | 2.20% |
12VIR | VIR BIOTECHNOLOGY INC | Healthcare | $1.59B | 2.19% |
13INSP | INSPIRE MEDICAL SYSTEMS INC | Healthcare | $1.46B | 2.00% |
14AKTS | AKTIS ONCOLOGY INC | Healthcare | $1.33B | 1.83% |
15XNCR | XENCOR INC | Healthcare | $1.30B | 1.78% |
16AZTA | AZENTA INC | Healthcare | $1.21B | 1.67% |
17NUTX | NUTEX HEALTH INC | Healthcare | $1.12B | 1.54% |
18BIOA | BIOAGE LABS INC | Healthcare | $1.01B | 1.39% |
19JANX | JANUX THERAPEUTICS INC | Healthcare | $992M | 1.36% |
20LBRX | LB PHARMACEUTICALS INC | Healthcare | $901M | 1.24% |
21SLDB | SOLID BIOSCIENCES INC | Healthcare | $859M | 1.18% |
22AVR | ANTERIS TECHNOLOGIES GLOBAL CORP | Healthcare | $823M | 1.13% |
23BBNX | BETA BIONICS INC | Healthcare | $771M | 1.06% |
24RIGL | RIGEL PHARMACEUTICALS INC | Healthcare | $750M | 1.03% |
25CSTL | CASTLE BIOSCIENCES INC | Healthcare | $733M | 1.01% |
26BBOT | BRIDGEBIO ONCOLOGY THERAPEUTICS INC | Healthcare | $686M | 0.94% |
27NGNE | NEUROGENE INC | Healthcare | $590M | 0.81% |
28FDMT | 4D MOLECULAR THERAPEUTICS INC | Healthcare | $575M | 0.79% |
29FLGT | FULGENT GENETICS INC | Healthcare | $573M | 0.79% |
30CTNM | CONTINEUM THERAPEUTICS INC | Healthcare | $532M | 0.73% |
31EIKN | EIKON THERAPEUTICS INC | Healthcare | $529M | 0.73% |
32ARVN | ARVINAS INC | Healthcare | $517M | 0.71% |
33DNA | GINKGO BIOWORKS HOLDINGS INC | Healthcare | $517M | 0.71% |
34SGMT | SAGIMET BIOSCIENCES INC | Healthcare | $479M | 0.66% |
35PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $453M | 0.62% |
36VREX | VAREX IMAGING CORP | Healthcare | $444M | 0.61% |
37BNTC | BENITEC BIOPHARMA INC | Healthcare | $439M | 0.60% |
38CCRN | CROSS COUNTRY HEALTHCARE INC | Healthcare | $428M | 0.59% |
39ABEO | ABEONA THERAPEUTICS INC | Healthcare | $399M | 0.55% |
40UPB | UPSTREAM BIO INC | Healthcare | $382M | 0.52% |
41ZNTL | ZENTALIS PHARMACEUTICALS INC | Healthcare | $364M | 0.50% |
42LYEL | LYELL IMMUNOPHARMA INC | Healthcare | $311M | 0.43% |
43TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $268M | 0.37% |
44QTTB | Q32 BIO INC | Healthcare | $255M | 0.35% |
45ARTV | ARTIVA BIOTHERAPEUTICS INC | Healthcare | $241M | 0.33% |
46RXST | RXSIGHT INC | Healthcare | $230M | 0.32% |
47UTMD | UTAH MEDICAL PRODUCTS INC | Healthcare | $222M | 0.31% |
48KROS | KEROS THERAPEUTICS INC | Healthcare | $211M | 0.29% |
49RNA | ATRIUM THERAPEUTICS INC | Healthcare | $208M | 0.29% |
50IMUX | IMMUNIC INC | Healthcare | $207M | 0.28% |
51DTIL | PRECISION BIOSCIENCES INC | Healthcare | $203M | 0.28% |
52ANIK | ANIKA THERAPEUTICS INC | Healthcare | $203M | 0.28% |
53AMWL | AMERICAN WELL CORP | Healthcare | $199M | 0.27% |
54TNXP | TONIX PHARMACEUTICALS HOLDING CORP | Healthcare | $198M | 0.27% |
55ACOG | ALPHA COGNITION INC | Healthcare | $185M | 0.25% |
56INGN | INOGEN INC | Healthcare | $178M | 0.24% |
57KRRO | KORRO BIO INC | Healthcare | $177M | 0.24% |
58ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $172M | 0.24% |
59CRBP | CORBUS PHARMACEUTICALS HOLDINGS INC | Healthcare | $167M | 0.23% |
60LENZ | LENZ THERAPEUTICS INC | Healthcare | $162M | 0.22% |
61PMN | PROMIS NEUROSCIENCES INC | Healthcare | $136M | 0.19% |
62VTVT | VTV THERAPEUTICS INC | Healthcare | $130M | 0.18% |
63AARD | AARDVARK THERAPEUTICS INC | Healthcare | $128M | 0.18% |
64CUE | CUE BIOPHARMA INC | Healthcare | $126M | 0.17% |
65ICCC | IMMUCELL CORP | Healthcare | $101M | 0.14% |
66RLYB | RALLYBIO CORP | Healthcare | $87M | 0.12% |
67FRMM | FORUM MARKETS INC | Healthcare | $83M | 0.11% |
68ACET | ADICET BIO INC | Healthcare | $76M | 0.10% |
69AGPU | AXE COMPUTE INC | Healthcare | $72M | 0.10% |
70LONA | LEONABIO INC | Healthcare | $68M | 0.09% |
71IMA | IMAGENEBIO INC | Healthcare | $61M | 0.08% |
72XLO | XILIO THERAPEUTICS INC | Healthcare | $53M | 0.07% |
73TIL | INSTIL BIO INC | Healthcare | $50M | 0.07% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $72.77B. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 57% toward Large, 14% toward Growth. Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1999 → July 2026; the right-hand end is the same value as the box’s dot. 73 names now. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Required>= 75.0%Actual75.9%Margin0.9%Close to the line. The engine flags this verdict as one a routine data rebuild could flip. Read it as borderline rather than settled — the margin beside it is the whole story.
Days required to liquidate the largest position at 20% of one day's dollar volume.
Required<= 7.0 daysActual7.1 daysMargin-0.1 days
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
1 verdict(s) sit within 1.0pp of their limit and can be flipped by a routine data rebuild; do not headline them, and always show the margin.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 73 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 329 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 81.5% | 27.8% |
| 3 yearsp.a. | 21.5% | 6.1% |
| 5 yearsp.a. | 4.1% | 2.2% |
| 10 yearsp.a. | 8.1% | 0.6% |
| Since inceptionp.a. | 11.4% | 4.5% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 24.7% | 14.9% |
| 2025 | 41.2% | 9.6% |
| 2024 | 7.1% | 3.5% |
| 2023 | -14.0% | -16.2% |
| 2022 | -19.3% | 2.1% |
| 2021 | -11.2% | -16.5% |
| 2020 | 38.2% | 10.3% |
| 2019 | 22.6% | 7.3% |
| 2018 | -7.4% | -16.6% |
| 2017 | 17.7% | 1.2% |
| 2016 | -3.5% | 8.5% |
| 2015 | 6.2% | -0.1% |
| 2014 | 29.6% | 2.3% |
| 2013 | 44.0% | -3.5% |
| 2012 | 15.5% | -4.7% |
| 2011 | 19.8% | 12.3% |
| 2010 | 26.0% | 15.8% |
| 2009 | 10.2% | -4.6% |
| 2008 | -35.3% | -16.8% |
| 2007 | -3.3% | -8.6% |
| 2006 | 17.1% | 15.0% |
| 2005 | 13.0% | 5.7% |
| 2004 | 23.0% | 24.3% |
| 2003 | 57.9% | 35.5% |
| 2002 | -16.3% | 8.5% |
| 2001 | 24.7% | 41.6% |
| 2000 | 61.0% | 26.2% |
| 199910 mo | -9.5% | -6.4% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare Book-to-Market Value Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Book-to-Market Value signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.